TABLE 1.

Group Characteristics

	Sex (% male)	Age at death (mean yr; SD)	Age at onset (mean yr; SD)	PMI (mean h; SD)	Brain weight (g; SD)	Braak stage V/VI (%)	Aβ plaque score (A3; %)	APOE E4 (%)
AD (n = 14)	57	81 (11)	72 (14)	19 (9)	1,197 (131)	78%	86%	33%
AD/TDP (n = 16)	44	80 (9)	69 (12)	18 (5)	1,141 (132)	81%	100%	39%
FTLD-TDP (n = 18)	50	68 (9)	59 (9)	13 (10)	1,039 (227)	0%	0%	4%
TDP type A (n = 5)	60	70 (10)	64 (12)	6 (2)	970 (77)	0%	0%	0%
TDP type B (n = 5)	80	67 (14)	59 (6)	16 (10)	1,370 (137)	0%	0%	0%
TDP type C (n = 8)	25	68 (4)	55 (5)	14 (11)	1,040 (232)	0%	0%	6%

Note: APOE genotyping was available for 38 participants and frequencies reflect the proportion of E4 allele present. A3 = severe amyloid-β score criteria according to the NIA-AA; AD = Alzheimer’s disease; AD/TDP = comorbid Alzheimer’s disease and transactive response DNA-binding protein 43; APOE E4 = apolipoprotein allele 4; FTLD-TDP = transactive response DNA-binding protein 43 pathology form of frontotemporal lobar degeneration; PMI = post-mortem interval; TDP = transactive response DNA-binding protein 43; h = hours; yr = years; SD = standard deviation.